Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Rabies virus glycoprotein (RVG) peptide is a nicotinic acetylcholine receptor (nAChR) antagonist (IC50 = 2.5 µM for the human receptor).1 Lipid nanoparticles (LNPs) conjugated to RVG peptide selectively traffic to the brain over the lungs and liver in rats.2 LNPs conjugated to RVG peptide and encapsulating the iron chelator and prolyl hydroxylase inhibitor deferoxamine (DFO; Item No. 14595) reduce iron levels in the striatum and substantia nigra, as well as decrease levels of reactive oxygen species (ROS) and malondialdehyde (MDA) and increase levels of superoxide dismutase (SOD) in the substantia nigra in a mouse model of MPTP-induced Parkinson's disease. RVG-containing and DFO-encapsulating LNPs also increase the latency to fall in the rotarod test in the same model.
WARNING This product is not for human or veterinary use.
1. Synthetic peptides corresponding to sequences of snake venom neurotoxins and rabies virus glycoprotein bind to the nicotinic acetylcholine receptor. Proteins 2(4), 298-307 (1987).
2. Correction to targeted brain delivery of rabies virus glycoprotein 29-